Loading...
XSHE300119
Market cap1.12bUSD
Jan 14, Last price  
17.67CNY
1D
2.32%
1Q
31.28%
Jan 2017
2.79%
IPO
28.47%
Name

Tianjin Ringpu Bio-Technology Co Ltd

Chart & Performance

D1W1MN
XSHE:300119 chart
P/E
18.10
P/S
3.65
EPS
0.98
Div Yield, %
1.99%
Shrs. gr., 5y
2.76%
Rev. gr., 5y
13.58%
Revenues
2.25b
+7.90%
146,100,179224,133,644285,355,542345,619,033587,713,347656,393,897754,904,372585,196,983792,834,473969,858,4931,047,334,4881,189,866,0121,466,580,5042,000,407,1062,007,138,3042,084,250,3992,248,962,053
Net income
453m
+30.64%
36,961,96043,321,87561,500,93182,539,811114,094,687144,079,002151,958,90327,128,623110,310,755132,782,489104,895,236118,978,853194,359,933398,196,538412,784,534346,698,684452,942,064
CFO
378m
-2.90%
19,145,45868,072,29564,590,619112,815,21190,285,52289,918,33188,684,156128,370,937225,265,709207,668,427107,573,523174,881,770383,608,950388,439,470382,628,909389,486,980378,196,328
Dividend
May 15, 20240.4 CNY/sh
Earnings
Apr 18, 2025

Profile

Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sales of veterinary biological products, veterinary drug preparations, functional additives, and veterinary raw materials in China. The company provides vaccines and drugs for poultry, swine, and other animals; pet products comprising pet rabies inactivated vaccine, recombinant canine-a interferon, inhalation anesthetics isoflurane and sevoflurane for dogs and cats, cefquinoxime sulfate for injection for prevention and treatment of pet bacterial diseases, heart disease drugs for dogs and cats, napril chewable tablets and other products; and waterfowl products, including duck tempusu live/inactivated vaccine, gosling plague refined egg yolk antibody, duck infectious serositis inactivated vaccine, duck viral hepatitis refined egg yolk antibody, duck plague live vaccine, florfenicol soluble powder, kanamycin injection, etc. It also offers antifungal products, such as natural plant extracts, immune polysaccharides, clostridium butyricum, lactobacillus plantarum, antibacterial peptides, enzyme preparations, acidulants, etc; disinfection and cleaning products, consisting of potassium hydrogen persulfate composite powder, benzyl trimethyl ammonium chloride solution, deca methyl ammonium bromide solution, sodium dichloroisocyanurate, iodine glycerin solution, etc.; and APIs comprising tilmicosin, tilmicosin phosphate, monbutone, tidiroxine, florfenicol, vonimulin hydrochloride, gamimycin, etc. The company was founded in 1998 and is based in Tianjin, China.
URL
http://www.ringpu.com
IPO date
Sep 17, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,248,962
7.90%
2,084,250
3.84%
Cost of revenue
1,562,626
1,595,345
Unusual Expense (Income)
NOPBT
686,336
488,905
NOPBT Margin
30.52%
23.46%
Operating Taxes
55,663
40,042
Tax Rate
8.11%
8.19%
NOPAT
630,673
448,864
Net income
452,942
30.64%
346,699
-16.01%
Dividends
(162,817)
(163,694)
Dividend yield
2.14%
1.88%
Proceeds from repurchase of equity
(44,927)
BB yield
0.59%
Debt
Debt current
548,184
685,521
Long-term debt
324,832
193,131
Deferred revenue
53,544
50,803
Other long-term liabilities
Net debt
(1,622,981)
(1,006,616)
Cash flow
Cash from operating activities
378,196
389,487
CAPEX
(244,483)
Cash from investing activities
(160,975)
Cash from financing activities
(272,461)
FCF
265,378
252,584
Balance
Cash
1,618,803
1,885,268
Long term investments
877,194
Excess cash
2,383,549
1,781,055
Stockholders' equity
2,448,010
2,307,738
Invested Capital
3,339,038
3,601,050
ROIC
18.17%
13.34%
ROCE
11.83%
9.00%
EV
Common stock shares outstanding
463,510
468,019
Price
16.39
-11.93%
18.61
-22.84%
Market cap
7,596,930
-12.78%
8,709,830
-22.59%
EV
6,282,531
7,982,809
EBITDA
827,381
604,473
EV/EBITDA
7.59
13.21
Interest
24,327
28,434
Interest/NOPBT
3.54%
5.82%